ArticleNature2024
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Article
- Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.Nature reviews. Urology · 2026Review
- Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Lancet2: Improved and accelerated somatic variant calling with joint multi-sample local assembly graphs.NAR genomics and bioinformatics · 2026Article
- Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Journal for immunotherapy of cancer · 2026Article
- Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026Review
- The newfound relationship between extrachromosomal DNAs and excised signal circles.FEBS letters · 2026Review
- Review
- Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.Genome biology · 2026Article
- Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma.International journal of molecular sciences · 2026Review
- Article
- DeepECC: a deep learning framework for genome-wide identification and analysis of human cancer eccDNAs.Nucleic acids research · 2026Article
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Extrachromosomal DNA and cancer: function, formation, and clinical implications.Journal of experimental & clinical cancer research : CR · 2026Review
- Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.Nature communications · 2026Article
- Extrachromosomal DNA in Solid Tumors-Landscape, Immune Effects, and Resistance to Targeted Therapy.Oncology research · 2026Review
- Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions.Frontiers in immunology · 2026Review
- Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing.BMC cancer · 2025Article
- From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management.Cancer biology & medicine · 2025Review
- APOBEC3A-Induced DNA Damage Drives Polymerase θ Dependency and Synthetic Lethality in Cancer.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Duy D Nguyen *Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
William F Hooper *New York Genome Center, New York, NY, USA.
Weisi Liu *Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Timothy R ChuNew York Genome Center, New York, NY, USA.
Heather GeigerNew York Genome Center, New York, NY, USA.
Jennifer M SheltonNew York Genome Center, New York, NY, USA.
Minita ShahNew York Genome Center, New York, NY, USA.
Zoe R GoldsteinNew York Genome Center, New York, NY, USA.
Lara WinterkornNew York Genome Center, New York, NY, USA.
Adrienne HellandNew York Genome Center, New York, NY, USA.
Michael SigourosCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-0328-8359
Jyothi ManoharCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Jenna MoyerCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-4599-2969
Majd Al AssaadCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Alissa SemaanCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Sandra CohenCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Florencia Madorsky RowdoCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8504-1690
David WilkesCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Mohamed OsmanDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Rahul R SinghDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Andrea SbonerCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-6915-3070
Henkel L ValentineNuclear Dynamics and Cancer program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Phillip AbboshNuclear Dynamics and Cancer program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Scott T TagawaDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-2777-8587
David M NanusDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Jones T NauseefDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-2302-4171
Cora N SternbergDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-3938-2627
Ana M MolinaDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Douglas ScherrSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Giorgio InghiramiCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-5566-0864
Juan Miguel MosqueraCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4666-6476
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8061-9617
Nicolas RobineNew York Genome Center, New York, NY, USA.ORCID 0000-0001-5698-8183
Bishoy M FaltasDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA. bmf9003@med.cornell.edu.ORCID 0000-0002-6432-1693
Funding
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MOptimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patientsU01CA260369 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI ABBOSH, PHILIP · 2021 to 2025
$2.0MTargeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancerR37CA279737 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Bishoy Morris Faltas · 2023 to 2026
$2.0MNCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS R37 CA279737NCI NIH HHS U01 CA260369
Abstract
Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity
Indexed as
DNA, CircularEvolution, MolecularMutagenesisMutationUrinary Bladder NeoplasmsAPOBEC DeaminasesCyclin D1DNA Copy Number VariationsDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedUrotheliumWhole Genome SequencingAPOBEC3 proteins, humanAPOBEC DeaminasesCCND1 protein, humanCyclin D1DNA, Circular
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.